APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cancer Immunotherapies

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Cancer Immunotherapies Industry Growth and Trends Forecast to 2032

20 December 2025107 pages

Choose your research edition.

Industry ResearchCancer Immunotherapies Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Immunotherapies Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Cancer Immunotherapies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Immunotherapies Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Immunotherapies Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Cancer Immunotherapies market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Cancer Immunotherapies is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Cancer Immunotherapies is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cancer Immunotherapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Cancer Immunotherapies include ARMO BioSciences (Eli Lilly), Bristol-Myers Squibb, Gilead Sciences, AstraZeneca, AbbVie, Amgen, Bayer, Pfizer and Roche, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Cancer Immunotherapies market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Cancer Immunotherapies market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Cancer Immunotherapies market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Cancer Immunotherapies.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Cancer Immunotherapies market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Cancer Immunotherapies Market by Company

ARMO BioSciences (Eli Lilly)

Bristol-Myers Squibb

Gilead Sciences

AstraZeneca

AbbVie

Amgen

Bayer

Pfizer

Roche

Merck

Novartis

Johnson & Johnson

Cancer Immunotherapies Segment by Type

Immunomodulators

Checkpoint Inhibitors

Adoptive Cell transfer

Monoclonal Antibodies (MABs)

Cancer Vaccines

Cancer Immunotherapies Segment by Application

Breast Cancer

Lymphoma

Colorectal Cancer

Melanoma

Non-Small Cell Lung Cancer

Leukemia

Cancer Immunotherapies Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Immunotherapies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Immunotherapies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Immunotherapies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Cancer Immunotherapies manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Cancer Immunotherapies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Immunomodulators Table 2. Major Company of Checkpoint Inhibitors Table 3. Major Company of Adoptive Cell transfer Table 4. Major Company of Monoclonal Antibodies (MABs) Table 5. Major Company of Cancer Vaccines Table 6. Global Cancer Immunotherapies Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Cancer Immunotherapies Sales by Type (2021-2026) & (k units) Table 8. Global Cancer Immunotherapies Sales Market Share in Volume by Type (2021-2026) Table 9. Global Cancer Immunotherapies Sales by Type (2021-2026) & (US$ Million) Table 10. Global Cancer Immunotherapies Sales Market Share in Value by Type (2021-2026) Table 11. Global Cancer Immunotherapies Price by Type (2021-2026) & (US$/unit) Table 12. Global Cancer Immunotherapies Sales by Type (2027-2032) & (k units) Table 13. Global Cancer Immunotherapies Sales Market Share in Volume by Type (2027-2032) Table 14. Global Cancer Immunotherapies Sales by Type (2027-2032) & (US$ Million) Table 15. Global Cancer Immunotherapies Sales Market Share in Value by Type (2027-2032) Table 16. Global Cancer Immunotherapies Price by Type (2027-2032) & (US$/unit) Table 17. North America Cancer Immunotherapies Sales by Type (2021-2026) & (k units) Table 18. North America Cancer Immunotherapies Sales by Type (2021-2026) & (US$ Million) Table 19. Europe Cancer Immunotherapies Sales by Type (2021-2026) & (k units) Table 20. Europe Cancer Immunotherapies Sales by Type (2021-2026) & (US$ Million) Table 21. Asia-Pacific Cancer Immunotherapies Sales by Type (2021-2026) & (k units) Table 22. Asia-Pacific Cancer Immunotherapies Sales by Type (2021-2026) & (US$ Million) Table 23. Latin America Cancer Immunotherapies Sales by Type (2021-2026) & (k units) Table 24. Latin America Cancer Immunotherapies Sales by Type (2021-2026) & (US$ Million) Table 25. Middle East and Africa Cancer Immunotherapies Sales by Type (2021-2026) & (k units) Table 26. Middle East and Africa Cancer Immunotherapies Sales by Type (2021-2026) & (US$ Million) Table 27. Cancer Immunotherapies Industry Trends Table 28. Cancer Immunotherapies Industry Drivers Table 29. Cancer Immunotherapies Industry Opportunities and Challenges Table 30. Cancer Immunotherapies Industry Restraints Table 31. Global Cancer Immunotherapies Sales Revenue by Company (US$ Million) & (2021-2026) Table 32. Global Cancer Immunotherapies Revenue Market Share by Company (2021-2026) Table 33. Global Cancer Immunotherapies Sales by Company (2021-2026) & (k units) Table 34. Global Cancer Immunotherapies Sales Share by Company (2021-2026) Table 35. Global Cancer Immunotherapies Market Price by Company (2021-2026) & (US$/unit) Table 36. Global Cancer Immunotherapies Industry Company Ranking, 2024 VS 2025 VS 2026 Table 37. Global Cancer Immunotherapies Major Company Production Sites and Headquarters Table 38. Global Cancer Immunotherapies Company, Product Type & Application Table 39. Global Cancer Immunotherapies Company Establishment Date Table 40. Global Company Market Concentration Ratio (CR5 and HHI) Table 41. Global Cancer Immunotherapies by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 42. Global Cancer Immunotherapies Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 43. Global Cancer Immunotherapies Sales by Region (2021-2026) & (k units) Table 44. Global Cancer Immunotherapies Sales Market Share in Volume by Region (2021-2026) Table 45. Global Cancer Immunotherapies Sales by Region (2021-2026) & (US$ Million) Table 46. Global Cancer Immunotherapies Sales Market Share in Value by Region (2021-2026) Table 47. Global Cancer Immunotherapies Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 48. Global Cancer Immunotherapies Sales by Region (2027-2032) & (k units) Table 49. Global Cancer Immunotherapies Sales Market Share in Volume by Region (2027-2032) Table 50. Global Cancer Immunotherapies Sales by Region (2027-2032) & (US$ Million) Table 51. Global Cancer Immunotherapies Sales Market Share in Value by Region (2027-2032) Table 52. Global Cancer Immunotherapies Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 53. Global Cancer Immunotherapies Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 54. Global Cancer Immunotherapies Sales by Application (2021-2026) & (k units) Table 55. Global Cancer Immunotherapies Sales Market Share in Volume by Application (2021-2026) Table 56. Global Cancer Immunotherapies Sales by Application (2021-2026) & (US$ Million) Table 57. Global Cancer Immunotherapies Sales Market Share in Value by Application (2021-2026) Table 58. Global Cancer Immunotherapies Price by Application (2021-2026) & (US$/unit) Table 59. Global Cancer Immunotherapies Sales by Application (2027-2032) & (k units) Table 60. Global Cancer Immunotherapies Sales Market Share in Volume by Application (2027-2032) Table 61. Global Cancer Immunotherapies Sales by Application (2027-2032) & (US$ Million) Table 62. Global Cancer Immunotherapies Sales Market Share in Value by Application (2027-2032) Table 63. Global Cancer Immunotherapies Price by Application (2027-2032) & (US$/unit) Table 64. North America Cancer Immunotherapies Sales by Application (2021-2026) & (k units) Table 65. North America Cancer Immunotherapies Sales by Application (2021-2026) & (US$ Million) Table 66. Europe Cancer Immunotherapies Sales by Application (2021-2026) & (k units) Table 67. Europe Cancer Immunotherapies Sales by Application (2021-2026) & (US$ Million) Table 68. Asia-Pacific Cancer Immunotherapies Sales by Application (2021-2026) & (k units) Table 69. Asia-Pacific Cancer Immunotherapies Sales by Application (2021-2026) & (US$ Million) Table 70. Latin America Cancer Immunotherapies Sales by Application (2021-2026) & (k units) Table 71. Latin America Cancer Immunotherapies Sales by Application (2021-2026) & (US$ Million) Table 72. Middle East and Africa Cancer Immunotherapies Sales by Application (2021-2026) & (k units) Table 73. Middle East and Africa Cancer Immunotherapies Sales by Application (2021-2026) & (US$ Million) Table 74. ARMO BioSciences (Eli Lilly) Company Information Table 75. ARMO BioSciences (Eli Lilly) Business Overview Table 76. ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Product Portfolio Table 78. ARMO BioSciences (Eli Lilly) Recent Development Table 79. Bristol-Myers Squibb Company Information Table 80. Bristol-Myers Squibb Business Overview Table 81. Bristol-Myers Squibb Cancer Immunotherapies Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Bristol-Myers Squibb Cancer Immunotherapies Product Portfolio Table 83. Bristol-Myers Squibb Recent Development Table 84. Gilead Sciences Company Information Table 85. Gilead Sciences Business Overview Table 86. Gilead Sciences Cancer Immunotherapies Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Gilead Sciences Cancer Immunotherapies Product Portfolio Table 88. Gilead Sciences Recent Development Table 89. AstraZeneca Company Information Table 90. AstraZeneca Business Overview Table 91. AstraZeneca Cancer Immunotherapies Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. AstraZeneca Cancer Immunotherapies Product Portfolio Table 93. AstraZeneca Recent Development Table 94. AbbVie Company Information Table 95. AbbVie Business Overview Table 96. AbbVie Cancer Immunotherapies Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. AbbVie Cancer Immunotherapies Product Portfolio Table 98. AbbVie Recent Development Table 99. Amgen Company Information Table 100. Amgen Business Overview Table 101. Amgen Cancer Immunotherapies Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Amgen Cancer Immunotherapies Product Portfolio Table 103. Amgen Recent Development Table 104. Bayer Company Information Table 105. Bayer Business Overview Table 106. Bayer Cancer Immunotherapies Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Bayer Cancer Immunotherapies Product Portfolio Table 108. Bayer Recent Development Table 109. Pfizer Company Information Table 110. Pfizer Business Overview Table 111. Pfizer Cancer Immunotherapies Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Pfizer Cancer Immunotherapies Product Portfolio Table 113. Pfizer Recent Development Table 114. Roche Company Information Table 115. Roche Business Overview Table 116. Roche Cancer Immunotherapies Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Roche Cancer Immunotherapies Product Portfolio Table 118. Roche Recent Development Table 119. Merck Company Information Table 120. Merck Business Overview Table 121. Merck Cancer Immunotherapies Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. Merck Cancer Immunotherapies Product Portfolio Table 123. Merck Recent Development Table 124. Novartis Company Information Table 125. Novartis Business Overview Table 126. Novartis Cancer Immunotherapies Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. Novartis Cancer Immunotherapies Product Portfolio Table 128. Novartis Recent Development Table 129. Johnson & Johnson Company Information Table 130. Johnson & Johnson Business Overview Table 131. Johnson & Johnson Cancer Immunotherapies Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 132. Johnson & Johnson Cancer Immunotherapies Product Portfolio Table 133. Johnson & Johnson Recent Development Table 134. North America Cancer Immunotherapies Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 135. North America Cancer Immunotherapies Sales by Country (2021-2026) & (k units) Table 136. North America Cancer Immunotherapies Sales Market Share by Country (2021-2026) Table 137. North America Cancer Immunotherapies Sales Forecast by Country (2027-2032) & (k units) Table 138. North America Cancer Immunotherapies Sales Market Share Forecast by Country (2027-2032) Table 139. North America Cancer Immunotherapies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 140. North America Cancer Immunotherapies Market Size by Country (2021-2026) & (US$ Million) Table 141. North America Cancer Immunotherapies Market Share by Country (2021-2026) Table 142. North America Cancer Immunotherapies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 143. North America Cancer Immunotherapies Market Share Forecast by Country (2027-2032) Table 144. Europe Cancer Immunotherapies Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 145. Europe Cancer Immunotherapies Sales by Country (2021-2026) & (k units) Table 146. Europe Cancer Immunotherapies Sales Market Share by Country (2021-2026) Table 147. Europe Cancer Immunotherapies Sales Forecast by Country (2027-2032) & (k units) Table 148. Europe Cancer Immunotherapies Sales Market Share Forecast by Country (2027-2032) Table 149. Europe Cancer Immunotherapies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 150. Europe Cancer Immunotherapies Market Size by Country (2021-2026) & (US$ Million) Table 151. Europe Cancer Immunotherapies Market Share by Country (2021-2026) Table 152. Europe Cancer Immunotherapies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 153. Europe Cancer Immunotherapies Market Share Forecast by Country (2027-2032) Table 154. Asia-Pacific Cancer Immunotherapies Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 155. Asia-Pacific Cancer Immunotherapies Sales by Country (2021-2026) & (k units) Table 156. Asia-Pacific Cancer Immunotherapies Sales Market Share by Country (2021-2026) Table 157. Asia-Pacific Cancer Immunotherapies Sales Forecast by Country (2027-2032) & (k units) Table 158. Asia-Pacific Cancer Immunotherapies Sales Market Share Forecast by Country (2027-2032) Table 159. Asia-Pacific Cancer Immunotherapies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 160. Asia-Pacific Cancer Immunotherapies Market Size by Country (2021-2026) & (US$ Million) Table 161. Asia-Pacific Cancer Immunotherapies Market Share by Country (2021-2026) Table 162. Asia-Pacific Cancer Immunotherapies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 163. Asia-Pacific Cancer Immunotherapies Market Share Forecast by Country (2027-2032) Table 164. Latin America Cancer Immunotherapies Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 165. Latin America Cancer Immunotherapies Sales by Country (2021-2026) & (k units) Table 166. Latin America Cancer Immunotherapies Sales Market Share by Country (2021-2026) Table 167. Latin America Cancer Immunotherapies Sales Forecast by Country (2027-2032) & (k units) Table 168. Latin America Cancer Immunotherapies Sales Market Share Forecast by Country (2027-2032) Table 169. Latin America Cancer Immunotherapies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 170. Latin America Cancer Immunotherapies Market Size by Country (2021-2026) & (US$ Million) Table 171. Latin America Cancer Immunotherapies Market Share by Country (2021-2026) Table 172. Latin America Cancer Immunotherapies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 173. Latin America Cancer Immunotherapies Market Share Forecast by Country (2027-2032) Table 174. Middle East and Africa Cancer Immunotherapies Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 175. Middle East and Africa Cancer Immunotherapies Sales by Country (2021-2026) & (k units) Table 176. Middle East and Africa Cancer Immunotherapies Sales Market Share by Country (2021-2026) Table 177. Middle East and Africa Cancer Immunotherapies Sales Forecast by Country (2027-2032) & (k units) Table 178. Middle East and Africa Cancer Immunotherapies Sales Market Share Forecast by Country (2027-2032) Table 179. Middle East and Africa Cancer Immunotherapies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 180. Middle East and Africa Cancer Immunotherapies Market Size by Country (2021-2026) & (US$ Million) Table 181. Middle East and Africa Cancer Immunotherapies Market Share by Country (2021-2026) Table 182. Middle East and Africa Cancer Immunotherapies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 183. Middle East and Africa Cancer Immunotherapies Market Share Forecast by Country (2027-2032) Table 184. Key Raw Materials Table 185. Raw Materials Key Suppliers Table 186. Cancer Immunotherapies Distributors List Table 187. Cancer Immunotherapies Customers List Table 188. Research Programs/Design for This Report Table 189. Authors List of This Report Table 190. Secondary Sources Table 191. Primary Sources List of Figures Figure 1. Cancer Immunotherapies Image Figure 2. Global Cancer Immunotherapies Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Immunotherapies Market Size (2021-2032) & (US$ Million) Figure 4. Global Cancer Immunotherapies Sales (2021-2032) & (k units) Figure 5. Immunomodulators Image Figure 6. Global Immunomodulators Sales YoY Growth (2021-2032) & (k units) Figure 7. Checkpoint Inhibitors Image Figure 8. Global Checkpoint Inhibitors Sales YoY Growth (2021-2032) & (k units) Figure 9. Adoptive Cell transfer Image Figure 10. Global Adoptive Cell transfer Sales YoY Growth (2021-2032) & (k units) Figure 11. Monoclonal Antibodies (MABs) Image Figure 12. Global Monoclonal Antibodies (MABs) Sales YoY Growth (2021-2032) & (k units) Figure 13. Cancer Vaccines Image Figure 14. Global Cancer Vaccines Sales YoY Growth (2021-2032) & (k units) Figure 15. Global Cancer Immunotherapies Market Size Overview by Type (2021-2032) & (US$ Million) Figure 16. Global Cancer Immunotherapies Market Share by Type 2025 VS 2032 Figure 17. North America Cancer Immunotherapies Sales Market Share in Volume by Type in 2025 Figure 18. North America Cancer Immunotherapies Sales Market Share in Value by Type in 2025 Figure 19. Europe Cancer Immunotherapies Sales Market Share in Volume by Type in 2025 Figure 20. Europe Cancer Immunotherapies Sales Market Share in Value by Type in 2025 Figure 21. Asia-Pacific Cancer Immunotherapies Sales Market Share in Volume by Type in 2025 Figure 22. Asia-Pacific Cancer Immunotherapies Sales Market Share in Value by Type in 2025 Figure 23. Latin America Cancer Immunotherapies Sales Market Share in Volume by Type in 2025 Figure 24. Latin America Cancer Immunotherapies Sales Market Share in Value by Type in 2025 Figure 25. Middle East and Africa Cancer Immunotherapies Sales Market Share in Volume by Type in 2025 Figure 26. Middle East and Africa Cancer Immunotherapies Sales Market Share in Value by Type in 2025 Figure 27. Global Top 5 and 10 Cancer Immunotherapies Players Market Share by Revenue in 2025 Figure 28. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Breast Cancer Image Figure 30. Global Breast Cancer Sales YoY Growth (2021-2032) & (k units) Figure 31. Lymphoma Image Figure 32. Global Lymphoma Sales YoY Growth (2021-2032) & (k units) Figure 33. Colorectal Cancer Image Figure 34. Global Colorectal Cancer Sales YoY Growth (2021-2032) & (k units) Figure 35. Melanoma Image Figure 36. Global Melanoma Sales YoY Growth (2021-2032) & (k units) Figure 37. Non-Small Cell Lung Cancer Image Figure 38. Global Non-Small Cell Lung Cancer Sales YoY Growth (2021-2032) & (k units) Figure 39. Leukemia Image Figure 40. Global Leukemia Sales YoY Growth (2021-2032) & (k units) Figure 41. Global Cancer Immunotherapies Market Size Overview by Application (2021-2032) & (US$ Million) Figure 42. Global Cancer Immunotherapies Market Share by Application 2025 VS 2032 Figure 43. North America Cancer Immunotherapies Sales Market Share in Volume by Application in 2025 Figure 44. North America Cancer Immunotherapies Sales Market Share in Value by Application in 2025 Figure 45. Europe Cancer Immunotherapies Sales Market Share in Volume by Application in 2025 Figure 46. Europe Cancer Immunotherapies Sales Market Share in Value by Application in 2025 Figure 47. Asia-Pacific Cancer Immunotherapies Sales Market Share in Volume by Application in 2025 Figure 48. Asia-Pacific Cancer Immunotherapies Sales Market Share in Value by Application in 2025 Figure 49. Latin America Cancer Immunotherapies Sales Market Share in Volume by Application in 2025 Figure 50. Latin America Cancer Immunotherapies Sales Market Share in Value by Application in 2025 Figure 51. Middle East and Africa Cancer Immunotherapies Sales Market Share in Volume by Application in 2025 Figure 52. Middle East and Africa Cancer Immunotherapies Sales Market Share in Value by Application in 2025 Figure 53. North America Cancer Immunotherapies Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. North America Cancer Immunotherapies Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. North America Cancer Immunotherapies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. North America Cancer Immunotherapies Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Europe Cancer Immunotherapies Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Europe Cancer Immunotherapies Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Cancer Immunotherapies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Europe Cancer Immunotherapies Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Cancer Immunotherapies Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 62. Asia-Pacific Cancer Immunotherapies Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Cancer Immunotherapies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Asia-Pacific Cancer Immunotherapies Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Latin America Cancer Immunotherapies Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 66. Latin America Cancer Immunotherapies Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Latin America Cancer Immunotherapies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Latin America Cancer Immunotherapies Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Middle East and Africa Cancer Immunotherapies Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 70. Middle East and Africa Cancer Immunotherapies Sales Share by Country: 2021 VS 2025 VS 2032 Figure 71. Middle East and Africa Cancer Immunotherapies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 72. Middle East and Africa Cancer Immunotherapies Market Share by Country: 2021 VS 2025 VS 2032 Figure 73. Cancer Immunotherapies Value Chain Figure 74. Key Raw Materials Price Figure 75. Manufacturing Cost Structure Figure 76. Cancer Immunotherapies Production Mode & Process Figure 77. Direct Comparison with Distribution Share Figure 78. Distributors Profiles Figure 79. Years Considered Figure 80. Research Process Figure 81. Key Executives Interviewed

Scope & coverage.

Types
  • Immunomodulators
  • Checkpoint Inhibitors
  • Adoptive Cell transfer
  • Monoclonal Antibodies (MABs)
  • Cancer Vaccines
Applications
  • Breast Cancer
  • Lymphoma
  • Colorectal Cancer
  • Melanoma
  • Non-Small Cell Lung Cancer
  • Leukemia
Companies covered
  • ARMO BioSciences (Eli Lilly)
  • Bristol-Myers Squibb
  • Gilead Sciences
  • AstraZeneca
  • AbbVie
  • Amgen
  • Bayer
  • Pfizer
  • Roche
  • Merck
  • Novartis
  • Johnson & Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Cancer Immunotherapies Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Cancer Immunotherapies Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Cancer Immunotherapies Market by Type
  6. 1.3.1 Immunomodulators
  7. 1.3.2 Checkpoint Inhibitors
  8. 1.3.3 Adoptive Cell transfer
  9. 1.3.4 Monoclonal Antibodies (MABs)
  10. 1.3.5 Cancer Vaccines
  11. 1.4 Global Cancer Immunotherapies Market Size by Type
  12. 1.4.1 Global Cancer Immunotherapies Market Size Overview by Type (2021-2032)
  13. 1.4.2 Global Cancer Immunotherapies Historic Market Size Review by Type (2021-2026)
  14. 1.4.3 Global Cancer Immunotherapies Forecasted Market Size by Type (2027-2032)
  15. 1.5 Key Regions Market Size by Type
  16. 1.5.1 North America Cancer Immunotherapies Sales Breakdown by Type (2021-2026)
  17. 1.5.2 Europe Cancer Immunotherapies Sales Breakdown by Type (2021-2026)
  18. 1.5.3 Asia-Pacific Cancer Immunotherapies Sales Breakdown by Type (2021-2026)
  19. 1.5.4 South America Cancer Immunotherapies Sales Breakdown by Type (2021-2026)
  20. 1.5.5 Middle East and Africa Cancer Immunotherapies Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Cancer Immunotherapies Industry Trends
  2. 2.2 Cancer Immunotherapies Industry Drivers
  3. 2.3 Cancer Immunotherapies Industry Opportunities and Challenges
  4. 2.4 Cancer Immunotherapies Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Cancer Immunotherapies Revenue (2021-2026)
  2. 3.2 Global Top Players by Cancer Immunotherapies Sales (2021-2026)
  3. 3.3 Global Top Players by Cancer Immunotherapies Price (2021-2026)
  4. 3.4 Global Cancer Immunotherapies Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Cancer Immunotherapies Major Company Production Sites & Headquarters
  6. 3.6 Global Cancer Immunotherapies Company, Product Type & Application
  7. 3.7 Global Cancer Immunotherapies Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Cancer Immunotherapies Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Cancer Immunotherapies Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Cancer Immunotherapies Tier 1, Tier 2, and Tier 3
4 Cancer Immunotherapies Regional Status and Outlook
  1. 4.1 Global Cancer Immunotherapies Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Cancer Immunotherapies Historic Market Size by Region
  3. 4.2.1 Global Cancer Immunotherapies Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Cancer Immunotherapies Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Cancer Immunotherapies Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Cancer Immunotherapies Forecasted Market Size by Region
  7. 4.3.1 Global Cancer Immunotherapies Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Cancer Immunotherapies Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Cancer Immunotherapies Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Cancer Immunotherapies by Application
  1. 5.1 Cancer Immunotherapies Market by Application
  2. 5.1.1 Breast Cancer
  3. 5.1.2 Lymphoma
  4. 5.1.3 Colorectal Cancer
  5. 5.1.4 Melanoma
  6. 5.1.5 Non-Small Cell Lung Cancer
  7. 5.1.6 Leukemia
  8. 5.2 Global Cancer Immunotherapies Market Size by Application
  9. 5.2.1 Global Cancer Immunotherapies Market Size Overview by Application (2021-2032)
  10. 5.2.2 Global Cancer Immunotherapies Historic Market Size Review by Application (2021-2026)
  11. 5.2.3 Global Cancer Immunotherapies Forecasted Market Size by Application (2027-2032)
  12. 5.3 Key Regions Market Size by Application
  13. 5.3.1 North America Cancer Immunotherapies Sales Breakdown by Application (2021-2026)
  14. 5.3.2 Europe Cancer Immunotherapies Sales Breakdown by Application (2021-2026)
  15. 5.3.3 Asia-Pacific Cancer Immunotherapies Sales Breakdown by Application (2021-2026)
  16. 5.3.4 South America Cancer Immunotherapies Sales Breakdown by Application (2021-2026)
  17. 5.3.5 Middle East and Africa Cancer Immunotherapies Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 ARMO BioSciences (Eli Lilly)
  2. 6.1.1 ARMO BioSciences (Eli Lilly) Company Information
  3. 6.1.2 ARMO BioSciences (Eli Lilly) Business Overview
  4. 6.1.3 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Product Portfolio
  6. 6.1.5 ARMO BioSciences (Eli Lilly) Recent Developments
  7. 6.2 Bristol-Myers Squibb
  8. 6.2.1 Bristol-Myers Squibb Company Information
  9. 6.2.2 Bristol-Myers Squibb Business Overview
  10. 6.2.3 Bristol-Myers Squibb Cancer Immunotherapies Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Bristol-Myers Squibb Cancer Immunotherapies Product Portfolio
  12. 6.2.5 Bristol-Myers Squibb Recent Developments
  13. 6.3 Gilead Sciences
  14. 6.3.1 Gilead Sciences Company Information
  15. 6.3.2 Gilead Sciences Business Overview
  16. 6.3.3 Gilead Sciences Cancer Immunotherapies Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Gilead Sciences Cancer Immunotherapies Product Portfolio
  18. 6.3.5 Gilead Sciences Recent Developments
  19. 6.4 AstraZeneca
  20. 6.4.1 AstraZeneca Company Information
  21. 6.4.2 AstraZeneca Business Overview
  22. 6.4.3 AstraZeneca Cancer Immunotherapies Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 AstraZeneca Cancer Immunotherapies Product Portfolio
  24. 6.4.5 AstraZeneca Recent Developments
  25. 6.5 AbbVie
  26. 6.5.1 AbbVie Company Information
  27. 6.5.2 AbbVie Business Overview
  28. 6.5.3 AbbVie Cancer Immunotherapies Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 AbbVie Cancer Immunotherapies Product Portfolio
  30. 6.5.5 AbbVie Recent Developments
  31. 6.6 Amgen
  32. 6.6.1 Amgen Company Information
  33. 6.6.2 Amgen Business Overview
  34. 6.6.3 Amgen Cancer Immunotherapies Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Amgen Cancer Immunotherapies Product Portfolio
  36. 6.6.5 Amgen Recent Developments
  37. 6.7 Bayer
  38. 6.7.1 Bayer Company Information
  39. 6.7.2 Bayer Business Overview
  40. 6.7.3 Bayer Cancer Immunotherapies Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Bayer Cancer Immunotherapies Product Portfolio
  42. 6.7.5 Bayer Recent Developments
  43. 6.8 Pfizer
  44. 6.8.1 Pfizer Company Information
  45. 6.8.2 Pfizer Business Overview
  46. 6.8.3 Pfizer Cancer Immunotherapies Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Pfizer Cancer Immunotherapies Product Portfolio
  48. 6.8.5 Pfizer Recent Developments
  49. 6.9 Roche
  50. 6.9.1 Roche Company Information
  51. 6.9.2 Roche Business Overview
  52. 6.9.3 Roche Cancer Immunotherapies Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Roche Cancer Immunotherapies Product Portfolio
  54. 6.9.5 Roche Recent Developments
  55. 6.10 Merck
  56. 6.10.1 Merck Company Information
  57. 6.10.2 Merck Business Overview
  58. 6.10.3 Merck Cancer Immunotherapies Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Merck Cancer Immunotherapies Product Portfolio
  60. 6.10.5 Merck Recent Developments
  61. 6.11 Novartis
  62. 6.11.1 Novartis Company Information
  63. 6.11.2 Novartis Business Overview
  64. 6.11.3 Novartis Cancer Immunotherapies Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Novartis Cancer Immunotherapies Product Portfolio
  66. 6.11.5 Novartis Recent Developments
  67. 6.12 Johnson & Johnson
  68. 6.12.1 Johnson & Johnson Company Information
  69. 6.12.2 Johnson & Johnson Business Overview
  70. 6.12.3 Johnson & Johnson Cancer Immunotherapies Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Johnson & Johnson Cancer Immunotherapies Product Portfolio
  72. 6.12.5 Johnson & Johnson Recent Developments
7 North America by Country
  1. 7.1 North America Cancer Immunotherapies Sales by Country
  2. 7.1.1 North America Cancer Immunotherapies Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Cancer Immunotherapies Sales by Country (2021-2026)
  4. 7.1.3 North America Cancer Immunotherapies Sales Forecast by Country (2027-2032)
  5. 7.2 North America Cancer Immunotherapies Market Size by Country
  6. 7.2.1 North America Cancer Immunotherapies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Cancer Immunotherapies Market Size by Country (2021-2026)
  8. 7.2.3 North America Cancer Immunotherapies Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Cancer Immunotherapies Sales by Country
  2. 8.1.1 Europe Cancer Immunotherapies Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Cancer Immunotherapies Sales by Country (2021-2026)
  4. 8.1.3 Europe Cancer Immunotherapies Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Cancer Immunotherapies Market Size by Country
  6. 8.2.1 Europe Cancer Immunotherapies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Cancer Immunotherapies Market Size by Country (2021-2026)
  8. 8.2.3 Europe Cancer Immunotherapies Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Cancer Immunotherapies Sales by Country
  2. 9.1.1 Asia-Pacific Cancer Immunotherapies Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Cancer Immunotherapies Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Cancer Immunotherapies Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Cancer Immunotherapies Market Size by Country
  6. 9.2.1 Asia-Pacific Cancer Immunotherapies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Cancer Immunotherapies Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Cancer Immunotherapies Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Cancer Immunotherapies Sales by Country
  2. 10.1.1 South America Cancer Immunotherapies Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Cancer Immunotherapies Sales by Country (2021-2026)
  4. 10.1.3 South America Cancer Immunotherapies Sales Forecast by Country (2027-2032)
  5. 10.2 South America Cancer Immunotherapies Market Size by Country
  6. 10.2.1 South America Cancer Immunotherapies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Cancer Immunotherapies Market Size by Country (2021-2026)
  8. 10.2.3 South America Cancer Immunotherapies Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Cancer Immunotherapies Sales by Country
  2. 11.1.1 Middle East and Africa Cancer Immunotherapies Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Cancer Immunotherapies Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Cancer Immunotherapies Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Cancer Immunotherapies Market Size by Country
  6. 11.2.1 Middle East and Africa Cancer Immunotherapies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Cancer Immunotherapies Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Cancer Immunotherapies Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Cancer Immunotherapies Value Chain Analysis
  2. 12.1.1 Cancer Immunotherapies Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Cancer Immunotherapies Production Mode & Process
  7. 12.2 Cancer Immunotherapies Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Cancer Immunotherapies Distributors
  10. 12.2.3 Cancer Immunotherapies Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst